Please assess the completion status of the following clinical trial:

Trial Title: DS-5565 Phase III Study for Renal Impairment in Japanese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At screening, creatinine clearance (using the Cockcroft-Gault equation): 15-59 mL/min~* At screening, a pain scale of ≥ 40 mm~* Type 1 or type 2 diabetes mellitus at screening (for patients with diabetic peripheral neuropathic pain DPNP only)-. Painful distal symmetric polyneuropathy (for patients with DPNP only)~* post-herpetic neuralgia PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening (for patients with PHN only)~Exclusion Criteria:~* HbA1c (National Glycohemoglobin Standardization Program) \> 10.0% (for patients with DPNP only)~* Previous use of neurolytic block (for patients with PHN only)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-5565 group (Type: EXPERIMENTAL): DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose

Based on this trial design, predict the completion outcome and termination type (if applicable).